medigraphic.com
ISSN 1561-3054 (Electronic)

2016, Number 1

<< Back Next >>

Rev Cubana Med Trop 2016; 68 (1)

Antimicrobial susceptibility in Cuban isolates of Vibrio cholerae O1 obtained from clinical samples

Fernández AA, Bravo FL, Aguila SA, Cruz IY, Illnait ZMT, Llop HA, Hernández MJL, Blanco AS, Bebelagua CD

Language: Spanish
References: 27
Page: 51-58
PDF size: 75.33 Kb.


ABSTRACT

Introduction: Re-emergence of cholera in Haiti created a new reservoir for the increase of the seventh pandemic. This resulted in its spread to the Dominican Republic and other Caribbean countries, such as Cuba and Mexico.
Objectives: Study the antimicrobial susceptibility of isolates of Vibrio cholerae O1, Ogawa serotype, El Tor biotype, obtained from patients during the cholera epidemiological event occurring in Cuba from June 2012 to August 2013.
Methods: A study was conducted of 144 V. cholerae isolates using the Bauer-Kirby method to determine in vitro susceptibility to nine antimicrobials: ampicillin, sulfonamide, trimethoprim/sulfamethoxazole, chloramphenicol, tetracycline, doxycycline, azithromycin, ciprofloxacin and gentamicin, in compliance with standards from the U.S. Clinical and Laboratory Standards Institute.
Results: All isolates were resistant to trimethoprim/sulfamethoxazole; 98.7% to sulfonamide and 90.3% to ampicillin. Intermediate sensitivity values were obtained for ciprofloxacin (30.6%) and chloramphenicol (27.1%). Sensitivity levels above 92% were found for first-line antimicrobials (doxycycline, tetracycline and azithromycin), as well as gentamicin. Multi-drug resistant strains were not found.
Conclusions: Results reveal the effectiveness in vitro of the antimicrobials used in Cuba to treat acute diarrheal disease caused by V. cholerae.


REFERENCES

  1. Boletín Epidemiológico IPK. Vol 23(39):305 [Citado el 22 de octubre de 2013]. Disponible en: http://www.ipk.sld.cu/bolepid2/bol52-05.htm

  2. Organización Panamericana de la Salud. Situación de salud en las Américas. 2013. [Citado el 22 de octubre de 2013]. Disponible en: http://www.paho.org/spanish/dd/ais/IB-folleto-2005.pdf

  3. John LR. Enfermedades infecciosas. En: Stites DP, Terr AI, Parslow TG, editores. Inmunología básica y clínica. México, DF.: El Manual Moderno; 1999. p. 827-37.

  4. Egli T, Koster W, Meile L. Patogenic microbes in water and food: changes and challenges. FEMS Mycrobiology Reviews. 2002;26:111-2.

  5. Khan WA, Saha D, Ahmed S, Salam MA, Bennish ML. Efficacy of Ci profloxacin for Treatment of Cholera Associated with Diminished Susceptibility to Ciprofloxacin to Vibrio cholerae O1. PLoS One. 2015;10(8):e0134921. Disponible en: 10.1371/journal.pone.0134921

  6. Antié A, Canovié P. Cholera once and nowadays. Med Projl. 2010;63(7-8):579-82.

  7. Sjölund-Karlsson M, Reimer A, Folster JP, Walker M, Dahourou GA, Batra DG, et al. Drug-Resistance Mechanisms in Vibrio cholerae O1 Outbreak Strain, Haiti, 2010. Emerg Infect Dis. 2011;17(11):2151-54.

  8. Bravo L, Fernández A, Ramírez M, Fernández C, Ledo Y, Correa Y, et al. Caracterización microbiológica de Vibrio cholerae no O1 aisladas de Cuba. Rev Cubana Med Trop. 2007;59(3):184-6.

  9. Koneman E, Allen S, Dowell V, Janda W, Sommers H y Winn W. Diagnóstico microbiológico. Editorial Médica Panamericana; 1998.

  10. Garrity GM, Bell JA, Lilburm TG. Taxonomic outline of the prokaryotes. En: Bergey ¢s Manual of systematic bacteriology. 2nd ed. Release 4.00; Oct 2003. [Citado el 10 de febrero de 2004]. Disponible en: http://dx.doi.org/10.1007/bergeysoutline200310

  11. Clinical and Laboratory Standard Institute (CLSI) Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; Approved Guideline-Second Edition; M45-A2 [ISBN 1-56238-732-4]. 2010;30(18):36-37.

  12. Clinical and Laboratory Standard Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. CLSI document M100-S24 [ISBN 1-56238-898-3]. 2014;34(1):68-75.

  13. Bauer A., Kirby W, Sherman T y Turck M. Antibiotic susceptibility testing by standardized single disk method. Am J Clin Path. 1996;45(4):485-94.

  14. Dean AG, Dean JA, Coulombier D, Brendel KA, Amith DC, Burton AH, et al. Epi Info Versión 6: A Word Proccesing, Database, and Statistics Program for Epidemikology on Microcomputers. Atlanta, GA: Centers for Desease Control; 1994.

  15. Shakya G, Kim DW, Clemens JD, Malla S, Upadhyaya BD, Dumra SP, et al. Phenotypic and genetic characterization of Vibrio cholerae O1 clinical isolates collected through national antimicrobial resistance surveillance network in Nepal. World J Microbiol Biotecnol. 2012;28(8):2671-8.

  16. Khuntia HK, Samal SK, Kar SK, Pal BB. An Ogawa cholera outbreak 6 months after the Inaba cholera outbreaks in India, 2006. J Microbiol Immunol Infect. 2010;43(2):133-7.

  17. Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001;32:331-50.

  18. World Health Organization Global Task Force on Cholera Control. First steps for managing an outbreak of acute diarrhoea. Geneva: The Organization; 2004. [citado 23 de mayo de 2011]. Disponible en: http://whqlibdoc.who.int/hq/2010/WHO_CDS_CSR_NCS_2003.7_Rev.2_eng.pdf

  19. Martínez-Fortún JA. Epidemiología (síntesis cronológica). Cuad Hist San. 1952;5.

  20. Delgado G. El cólera morbo asiático en Cuba. Apuntes históricos y bibliográficos. Cuad Hist Sal Pub. 1993;78.

  21. Marin MA, Thompson CC, Freitas FC, Fonseca EL, Aboderin AO, Zailani SB, et al. Cholera Outbreaks in Nigeria Are Associated with Multidrug Resistant Atypical El Tor and Non-O1/Non-O139 Vibrio cholerae. PLoS Negl Trop Dis. 2013;7(2):e2049.

  22. Dutta D, Chowdhury G, Pazhaniv G, Guin S, Dutta S, Ghosh S, et al. V. cholerae Non-O1, Non-O139 Serogroups and Cholera-like Diarrhea, Kolkata, India. Emerg Infect Dis. 2013 [citado 12 de enero de 2014]. http://dx.doi.org/10. 3201/eid1903.121156

  23. Talkington D, Bopp Ch, Tarr Ch, Parsons MB, Dahourou G, Freeman M, et al. Characterization of Toxigenic Vibrio cholerae from Haiti, 2010-2011. Emerg Infect Dis. 2011;17(11):2122-9.

  24. Cabrera LE, Bravo L, Ramírez MM, Llop A, Fernández A, Morier L, et al. Susceptibilidad a los antimicrobianos y factores de virulencia en cepas de Vibrio cholerae no-O1 aisladas de pacientes con enfermedad diarreica aguda. Rev Biomed. 2008;19(3):138-44.

  25. Majano A, Bravo L, A. Fernández, M. Ramírez. Caracterización fenotípica de bacilos gramnegativos, anaerobios facultativos, oxidasa positivas aisladas de pacientes con enfermedad diarreica aguda. Rev Biomed. 2009;20:25-32.

  26. Bakhshi B, Eftekhari N, Pourshafie MR. Genetic Elements Associated With Antimicrobial Resistance Among Intestinal Bacteria Jundishapur. J Microbiol. 2014;7(5):e9924.

  27. Dong C, Zhang X, Bao C, Zhu Y, Zhuang L, Tan Z, et al. Antibiotic resistance and molecular characterization of Vibrio cholera strains isolated from an outbreak of cholera epidemic in Jiangsu province. Zhonghua Yu Fang Yi Xue Za Zhi. 2015 Feb;49(2):128-31.




2020     |     www.medigraphic.com